Status and phase
Conditions
Treatments
About
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
Full description
The total study duration from the screening visit to the completion visit is approximately 76 weeks and includes a screening period (28-30 days), a placebo-controlled treatment period (24 weeks) and a treatment extension period (48 weeks).
The participant will start treatment at the baseline visit and follow a 12-week dosing schedule with either eptinezumab (100 or 300 milligrams [mg]) or placebo by intraveneous (IV) infusion. Participants who were assigned to placebo in the placebo-controlled treatment period, will be randomly allocated to one of two treatment groups: eptinezumab 300 mg or eptinezumab 100 mg.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other in- and exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
892 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal